Adamas Pharma rises after IPO raises $48 million

Shares of Adamas Pharmaceuticals rose Thursday after the drug developer's initial public offering raised $48 million.

The offering of 3 million shares priced at $16 each, the low end of an expected range of $16 to $18.

In morning trading, the stock added $1, or 6.3 percent, to $17.

Adamas Pharmaceuticals Inc. is developing drugs that treat central nervous system disorders such as Parkinson's and Alzheimer's disease. It worked with Forest Laboratories Inc. on Namenda XR, an extended-release version of a Forest drug that treats Alzheimer's. The two companies have been studying a that combines Namenda XR with donepezil, or Aricept. Forest filed for approval of that pill in March.

Shares of the Emeryville, Calif., company are trading under the symbol "ADMS" on the Nasdaq Global Market.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Veeva Systems stock soars on debut

Oct 16, 2013

Shares of Veeva Systems Inc. are soaring in their trading debut Wednesday after the cloud-based software company raised about $261 million in its initial public offering.

Recommended for you

Powdered measles vaccine found safe in early clinical trials

10 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.